Furthermore, patients with HER2-negative breast cancer benefit from postneoadjuvant capecitabine if they do not present with pCR, especially the subgroups with TNBC and one to three metastatic lymph nodes after PST [20]. Here, ERBB2 is linked to breast carcinoma.